Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre Marie Girard, Alexander Wong, Norma Porteiro, Susan Swindells, Jacques Reynes, Sebastian Noe, Conn Harrington, Carlos Martín Español, Carolina Acuipil, Asma Aksar, Yuanyuan Wang, Susan L. Ford, Herta Crauwels, Veerle van Eygen, Rodica Van Solingen-Ristea, Christine L. LathamShanker Thiagarajah, Ronald D’Amico, Kimberly Y. Smith, Kati Vandermeulen, William R. Spreen

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study'. Together they form a unique fingerprint.

Medicine & Life Sciences